AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

CVS GROUP PLC

Director's Dealing Jan 19, 2024

7590_dirs_2024-01-19_2d71dc45-e807-4722-a461-a3ba11ba2c20.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3447A

CVS Group plc

19 January 2024

19 January 2024

CVS Group Plc

("CVS" or the "Company")

Exercise of SAYE Options and PDMR Dealing

CVS, one of the UK's leading providers of integrated veterinary services, announces that on 19 January 2024, options over a total of 6,126 ordinary shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group 2020 SAYE Plan (2020/2024), at an exercise price of £10.09. 

The issuance of shares in connection with the SAYE Exercise was fully satisfied by 6,126 Ordinary Shares held by the CVS Group Employee Benefit Trust (the "EBT"). Following the SAYE Exercise, a total of                

645 Ordinary Shares are held by the EBT, representing approximately 0.001% of the Company's total voting rights.

Ben Jacklin, Deputy CEO exercised options over 570 Ordinary Shares in the Company.  The balance of the options were exercised by certain other employees and former employees of the Company.

Following his option exercise, Ben Jacklin, along with any persons closely associated, holds a beneficial interest in 37,284 Ordinary Shares in the Company, representing approximately 0.052% of the total voting rights of the Company, calculated on the same basis.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Contacts:

CVS Group plc                                                                                                                                via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker)                                                 +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

Berenberg (Joint Broker)                                                                                          +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR)                                                                                             

Geoffrey Pelham-Lane                                                                                +44 (0)7733 124 226

Ginny Pulbrook                                                                                                     +44 (0)7961 315 138

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Ben Jacklin
2 Reason for the notification
a) Position/status Deputy CEO
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name CVS Group plc
b) LEI 213800J41XDQ2NX48O05
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.2 pence each

GB00B2863827

b)

Nature of the transaction

Exercise of options under the 2020 SAYE Plan (1 January   2024 maturity)

c)

Price(s) and volume(s)

Price(s) Volume
£10.09 570

d)

Aggregated information

- Aggregated volume

- Price

N/A - single transaction

e)

Date of the transaction

19 January 2024

f)

Place of the transaction

Outside a trading Venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHZKLFFZFLLBBL

Talk to a Data Expert

Have a question? We'll get back to you promptly.